Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 5/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24861749 | 0.93 | PTGER4 (0.56) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL30331265 | 0.93 | PTGER4 (0.61) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL28699766 | 0.93 | PTGER4 (0.61) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL24861836 | 0.93 | PTGER4 (0.61) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL24861748 | 0.90 | PTGER4 (0.70) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL24861818 | 0.90 | PTGER4 (0.70) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL26420246 | 0.86 | PTGER4 (0.59) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL24861838 | 0.86 | PTGER4 (0.55) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL28699767 | 0.84 | PTGER4 (0.57) | PTGER4PTGER2LMNAALDH1A1PHGDH | |
| SCHEMBL26420454 | 0.83 | PTGER4 (0.60) | PTGER4PTGER2PHGDHACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | PTGER4 1/4885PTGER2 3/4885LMNA 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.